Masanobu Takahashi

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 135 publications

SMARCB1/INI1-deficient Undifferentiated Carcinoma Presenting as Cancer of Unknown Primary with Massive Hepatic Involvement: Transient Response to FOLFOX plus Nivolumab.

SMARCB1/INI1-deficient Undifferentiated Carcinoma Presenting as Cancer of Unknown Primary with Massive Hepatic Involvement: Transient Response to FOLFOX plus Nivolumab.

Journal: Internal medicine (Tokyo, Japan)
Published: August 10, 2026

Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study.

Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study.

Journal: Frontiers in oncology
Published: April 29, 2026

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Journal: JCO precision oncology
Published: April 23, 2026

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213.

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Postoperative adjuvant eribulin in high-risk patients with soft tissue sarcoma: A retrospective study of eight cases.

Postoperative adjuvant eribulin in high-risk patients with soft tissue sarcoma: A retrospective study of eight cases.

Journal: Rare tumors
Published: January 24, 2026

Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers.

Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 18, 2026

New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.

New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.

Journal: Cancer science
Published: December 10, 2025

Entrapment of a Guidewire Caused by the Chiari Network during Implantation of a Central Venous Port.

Entrapment of a Guidewire Caused by the Chiari Network during Implantation of a Central Venous Port.

Journal: Internal medicine (Tokyo, Japan)
Published: November 05, 2025

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations.

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations.

Journal: Frontiers in oncology
Published: October 30, 2025

Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.

Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.

Journal: Japanese journal of clinical oncology
Published: October 24, 2025

A Case Report of Alpha-Fetoprotein-Producing Pancreatic Neuroendocrine Tumor and Review of the Literature.

A Case Report of Alpha-Fetoprotein-Producing Pancreatic Neuroendocrine Tumor and Review of the Literature.

Journal: International journal of surgical pathology
Published: October 06, 2025

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Journal: Nature medicine
Published: September 27, 2025
Showing 1-12 of 135

Last Updated: 09/26/2026